{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for zoledronic root_Display\ Name in Display Name (approximate match)
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 347
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
AtopiCream HC by VetriMax Veterinary Products, LLC
(2017)
Source URL:
First approved in 2017
Source:
AtopiCream HC by VetriMax Veterinary Products, LLC
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
M020
(2017)
Source URL:
First approved in 2015
Source:
M020
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2013)
Source URL:
First approved in 2009
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2012)
Source URL:
First approved in 2008
Source:
M020
Source URL:
Class:
CONCEPT
Status:
US Approved Rx
(2024)
Source:
NDA218784
(2024)
Source URL:
First approved in 2024
Source:
NDA218784
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Vorasidenib (also known as AG 881) was developed as an isocitrate dehydrogenase (IDH) type 1 in the cytoplasm and type 2 in the mitochondria, with potential antineoplastic activity. It is known that IDH is an essential enzyme for cellular respiration in the tricarboxylic acid (TCA) cycle. Isocitrate dehydrogenases 1 and 2 (IDH1/2) are homodimeric enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid cycle. Vorasidenib participated in phase I clinical trials in patients with advanced hematologic malignancies and in gliomas.
